KalVista presents data on HAE at ACAAI 2022 meeting

KalVista Pharmaceuticals presented two posters at the 2022 meeting of the American College of Allergy, Asthma & Immunology, AACI, in Louisville, Kentucky. The first highlighted new data that reveals the significant impact of HAE attacks on the mental health, daily activities, and quality of life for people living with hereditary angioedema, HAE, receiving either parenterally delivered on-demand only treatment or prophylaxis with on-demand treatment for breakthrough attacks. More than half of people with HAE felt unable to participate in important events or activities, while nearly half felt ‘less than 100% themselves’ due to HAE. The second presentation focused on injection- or infusion-related adverse drug reactions, ADRs, reported in the FDA’s Adverse Event Reporting System, FAERS, for currently approved on-demand hereditary angioedema, HAE, therapies. The five most frequently reported ADRs were injection site pain, site swelling, site erythema, access site complications/malfunctions, and incorrect route of product administration. "Both HAE patient feedback and FAERS data suggest that there is still a significant unmet need for on-demand treatments that have greater ease and less traumatic routes of administration," said Andrew Crockett, Chief Executive Officer of KalVista. "This is exactly why we are developing our pipeline of oral therapies, to improve the treatment experience and ultimately the lives of people living with HAE."